Tirzepatide + AOD-9604 Stack (Dual-Vial Metabolic Kit)
Analytical Standards & Laboratory Handling
Verified laboratory protocols, reconstitution parameters, and handling guidelines.
Pharmacological Profile & Mechanism of Action
What it is: A synergistic metabolic research stack pairing Tirzepatide (10mg dual GIP/GLP-1 receptor co-agonist) with AOD-9604 (5mg lipolytic C-terminal fragment of hGH) in two separate sterile analytical vials.
How it works: Tirzepatide delivers systemic metabolic optimization by delaying gastric motility, elevating glucose-dependent insulin secretion, and modulating hypothalamic satiety centers. Concurrently, AOD-9604 selectively upregulates beta-3 adrenergic receptor pathways in white adipose tissue, stimulating lipolytic triglyceride breakdown and inhibiting de-novo lipogenesis without cross-reacting with the IGF-1 axis.
CRITICAL LABORATORY RECONSTITUTION & ASSAY HANDLING: Reconstitute both vials separately. Tirzepatide is administered once weekly; AOD-9604 is administered daily morning fasted.
Compound & Molecular Specifications
Certificate of Analysis StandardsFrequently Stacked with Tirzepatide
Clinically verified combinations activating complementary physiological pathways without receptor competition.
AOD-9604 (Lipolytic Fragment)
Tirzepatide centrally suppresses appetite, improves glycemic control, and downregulates hepatic de novo lipogenesis via GLP-1/GIP. AOD-9604 acts peripherally on adipocyte beta-3 adrenergic receptors to trigger active lipolysis and fat breakdown without interfering with blood glucose or insulin sensitivity.
BPC-157 (Pentadecapeptide)
GLP-1 receptor agonists can cause transient delayed gastric emptying, nausea, and mucosal irritation. BPC-157 provides direct cytoprotective benefits across gastric epithelium, reducing gut discomfort while incretins drive metabolic weight loss.
